What we know about MSC therapy for stroke recovery.

Ischemic stroke kills brain tissue immediately and triggers a cascade of secondary injury, neuroinflammation, blood-brain-barrier disruption, oxidative damage, that continues for days and influences recovery for months. The clinical opportunity for MSCs sits in that second phase. The literature is smaller than the osteoarthritis literature, but the mechanistic logic is among the strongest in regenerative medicine.

What MSCs are thought to do

The candidate mechanisms in stroke recovery are immunomodulation of the post-ischemic inflammatory response, angiogenesis in the peri-infarct region, and indirect neurogenic signalling that supports endogenous neural progenitor activity. These are the same mechanisms we have written about in how effective is MSC, applied to one of the highest-stakes recovery windows in medicine.

Importantly, none of the leading mechanistic explanations involves MSCs differentiating into neurons in any clinically meaningful quantity. The benefit, where it exists, is signal-mediated and modulatory, not regenerative in the literal cell-replacement sense.

What the trials show

Phase I and Phase II trials of intravenous MSCs in subacute ischemic stroke have consistently shown safety and feasibility. Efficacy signals, measured on modified Rankin Scale, Fugl-Meyer scores, and NIH Stroke Scale, are present but variable. The best signals come from trials that treated within six to eight weeks of the index event, used adequate cell doses (typically 1-2 million cells per kilogram), and ran rehabilitation in parallel.

What the data does not support yet is administering MSCs in the hyperacute phase as a substitute for thrombolysis or thrombectomy. Standard stroke care comes first, always, and MSC therapy is a question for the recovery phase, not the rescue phase. Any patient considering this conversation is in it because their acute care was handled well, and a stable recovery trajectory needs to be optimised.

How we think about it in clinic

A typical case at our stem-cell technology programme is a patient four to ten weeks post-stroke, with stable medical status, neurology clearance, and an active rehabilitation programme. The MSC protocol runs alongside the rehabilitation, not as a replacement for it. The most important variable for outcome remains the rehabilitation dose, quality and consistency of motor, speech and cognitive work, which is true for every modality of stroke recovery.

Our cardiology consultant Dr. Sukawit Limwananon reviews any post-stroke patient before they enter a regenerative protocol, because the cardiovascular substrate that produced the stroke is rarely benign and often the most consequential variable for the next twelve months.

Who is unlikely to benefit

Patients more than twelve to eighteen months post-stroke. Patients with extensive established infarction and chronic atrophy. Patients with ongoing uncontrolled cardiovascular risk that has not been addressed. Patients without access to consistent rehabilitation. In each case the honest conversation is not 'this might still work', it is 'the marginal benefit of cell therapy is small relative to the things we know move outcomes.'

The honest framing

MSC therapy in stroke recovery is one of the higher-conviction applications of regenerative medicine outside orthopaedics. It is also one of the most easily oversold. The right framing is that it is an adjunct to a well-run recovery programme, plausibly improving the slope of recovery during the months when the brain is most plastic. It is not a salvage therapy for chronic deficit. It is not a substitute for rehabilitation. And it is not, in our practice, something we offer without a stroke neurologist in the room.

If you want the broader context on what regenerative medicine can and can't currently deliver, the read is autologous vs allogeneic, why our chain of custody matters, because the cell substrate matters at least as much as the indication.